2018-2023 Global Performance Enhancing Drugs Consumption Market Report

August 2018 | 133 pages | ID: 2827CF1EC84EN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Performance Enhancing Drugs market for 2018-2023.

Performance-enhancing drugs (PED), are substances that are used to improve any form of activity performance in humans.
A well-known example of PED involves doping in sport, where banned physical performance–enhancing drugs are used by athletes and bodybuilders. Athletic performance-enhancing substances are sometimes referred to as ergogenic aids. Cognitive performance-enhancing drugs, commonly called nootropics, are sometimes used by students to improve academic performance. Performance-enhancing substances are also used by military personnel to enhance combat performance.
Over the next five years, LPI(LP Information) projects that Performance Enhancing Drugs will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.

This report presents a comprehensive overview, market shares, and growth opportunities of Performance Enhancing Drugs market by product type, application, key manufacturers and key regions.

To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:

Segmentation by product type:

• Ergogenic Aids
• Nootropic

Segmentation by application:

• Athletes
• Body Builders
• Students
• Militaries

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Spain
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:

• Taj Pharmaceuticals
• Balkan Pharmaceuticals
• Bayer
• AstraZeneca
• Novo Nordisk
• BrainAlert
• Douglas Laboratories
• Onnit Labs
• Eli Lilly And Company

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives

• To study and analyze the global Performance Enhancing Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
• To understand the structure of Performance Enhancing Drugs market by identifying its various subsegments.
• Focuses on the key global Performance Enhancing Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
• To analyze the Performance Enhancing Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
• To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
• To project the consumption of Performance Enhancing Drugs submarkets, with respect to key regions (along with their respective key countries).
• To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
• To strategically profile the key players and comprehensively analyze their growth strategies.

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Economic Indicators
1.6 Currency Considered

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Performance Enhancing Drugs Consumption 2013-2023
  2.1.2 Performance Enhancing Drugs Consumption CAGR by Region
2.2 Performance Enhancing Drugs Segment by Type
  2.2.1 Ergogenic Aids
  2.2.2 Nootropic
2.3 Performance Enhancing Drugs Consumption by Type
  2.3.1 Global Performance Enhancing Drugs Consumption Market Share by Type (2013-2018)
  2.3.2 Global Performance Enhancing Drugs Revenue and Market Share by Type (2013-2018)
  2.3.3 Global Performance Enhancing Drugs Sale Price by Type (2013-2018)
2.4 Performance Enhancing Drugs Segment by Application
  2.4.1 Athletes
  2.4.2 Body Builders
  2.4.3 Students
  2.4.4 Militaries
2.5 Performance Enhancing Drugs Consumption by Application
  2.5.1 Global Performance Enhancing Drugs Consumption Market Share by Application (2013-2018)
  2.5.2 Global Performance Enhancing Drugs Value and Market Share by Application (2013-2018)
  2.5.3 Global Performance Enhancing Drugs Sale Price by Application (2013-2018)

3 GLOBAL PERFORMANCE ENHANCING DRUGS BY PLAYERS

3.1 Global Performance Enhancing Drugs Sales Market Share by Players
  3.1.1 Global Performance Enhancing Drugs Sales by Players (2016-2018)
  3.1.2 Global Performance Enhancing Drugs Sales Market Share by Players (2016-2018)
3.2 Global Performance Enhancing Drugs Revenue Market Share by Players
  3.2.1 Global Performance Enhancing Drugs Revenue by Players (2016-2018)
  3.2.2 Global Performance Enhancing Drugs Revenue Market Share by Players (2016-2018)
3.3 Global Performance Enhancing Drugs Sale Price by Players
3.4 Global Performance Enhancing Drugs Manufacturing Base Distribution, Sales Area, Product Types by Players
  3.4.1 Global Performance Enhancing Drugs Manufacturing Base Distribution and Sales Area by Players
  3.4.2 Players Performance Enhancing Drugs Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 PERFORMANCE ENHANCING DRUGS BY REGIONS

4.1 Performance Enhancing Drugs by Regions
  4.1.1 Global Performance Enhancing Drugs Consumption by Regions
  4.1.2 Global Performance Enhancing Drugs Value by Regions
4.2 Americas Performance Enhancing Drugs Consumption Growth
4.3 APAC Performance Enhancing Drugs Consumption Growth
4.4 Europe Performance Enhancing Drugs Consumption Growth
4.5 Middle East & Africa Performance Enhancing Drugs Consumption Growth

5 AMERICAS

5.1 Americas Performance Enhancing Drugs Consumption by Countries
  5.1.1 Americas Performance Enhancing Drugs Consumption by Countries (2013-2018)
  5.1.2 Americas Performance Enhancing Drugs Value by Countries (2013-2018)
5.2 Americas Performance Enhancing Drugs Consumption by Type
5.3 Americas Performance Enhancing Drugs Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC Performance Enhancing Drugs Consumption by Countries
  6.1.1 APAC Performance Enhancing Drugs Consumption by Countries (2013-2018)
  6.1.2 APAC Performance Enhancing Drugs Value by Countries (2013-2018)
6.2 APAC Performance Enhancing Drugs Consumption by Type
6.3 APAC Performance Enhancing Drugs Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 EUROPE

7.1 Europe Performance Enhancing Drugs by Countries
  7.1.1 Europe Performance Enhancing Drugs Consumption by Countries (2013-2018)
  7.1.2 Europe Performance Enhancing Drugs Value by Countries (2013-2018)
7.2 Europe Performance Enhancing Drugs Consumption by Type
7.3 Europe Performance Enhancing Drugs Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Performance Enhancing Drugs by Countries
  8.1.1 Middle East & Africa Performance Enhancing Drugs Consumption by Countries (2013-2018)
  8.1.2 Middle East & Africa Performance Enhancing Drugs Value by Countries (2013-2018)
8.2 Middle East & Africa Performance Enhancing Drugs Consumption by Type
8.3 Middle East & Africa Performance Enhancing Drugs Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers and Impact
  9.1.1 Growing Demand from Key Regions
  9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 MARKETING, DISTRIBUTORS AND CUSTOMER

10.1 Sales Channel
  10.1.1 Direct Marketing
  10.1.2 Indirect Marketing
10.2 Performance Enhancing Drugs Distributors
10.3 Performance Enhancing Drugs Customer

11 GLOBAL PERFORMANCE ENHANCING DRUGS MARKET FORECAST

11.1 Global Performance Enhancing Drugs Consumption Forecast (2018-2023)
11.2 Global Performance Enhancing Drugs Forecast by Regions
  11.2.1 Global Performance Enhancing Drugs Forecast by Regions (2018-2023)
  11.2.2 Global Performance Enhancing Drugs Value Forecast by Regions (2018-2023)
  11.2.3 Americas Consumption Forecast
  11.2.4 APAC Consumption Forecast
  11.2.5 Europe Consumption Forecast
  11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
  11.3.1 United States Market Forecast
  11.3.2 Canada Market Forecast
  11.3.3 Mexico Market Forecast
  11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
  11.4.1 China Market Forecast
  11.4.2 Japan Market Forecast
  11.4.3 Korea Market Forecast
  11.4.4 Southeast Asia Market Forecast
  11.4.5 India Market Forecast
  11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
  11.5.1 Germany Market Forecast
  11.5.2 France Market Forecast
  11.5.3 UK Market Forecast
  11.5.4 Italy Market Forecast
  11.5.5 Russia Market Forecast
  11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
  11.6.1 Egypt Market Forecast
  11.6.2 South Africa Market Forecast
  11.6.3 Israel Market Forecast
  11.6.4 Turkey Market Forecast
  11.6.5 GCC Countries Market Forecast
11.7 Global Performance Enhancing Drugs Forecast by Type
11.8 Global Performance Enhancing Drugs Forecast by Application

12 KEY PLAYERS ANALYSIS

12.1 Taj Pharmaceuticals
  12.1.1 Company Details
  12.1.2 Performance Enhancing Drugs Product Offered
  12.1.3 Taj Pharmaceuticals Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.1.4 Main Business Overview
  12.1.5 Taj Pharmaceuticals News
12.2 Balkan Pharmaceuticals
  12.2.1 Company Details
  12.2.2 Performance Enhancing Drugs Product Offered
  12.2.3 Balkan Pharmaceuticals Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.2.4 Main Business Overview
  12.2.5 Balkan Pharmaceuticals News
12.3 Bayer
  12.3.1 Company Details
  12.3.2 Performance Enhancing Drugs Product Offered
  12.3.3 Bayer Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.3.4 Main Business Overview
  12.3.5 Bayer News
12.4 AstraZeneca
  12.4.1 Company Details
  12.4.2 Performance Enhancing Drugs Product Offered
  12.4.3 AstraZeneca Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.4.4 Main Business Overview
  12.4.5 AstraZeneca News
12.5 Novo Nordisk
  12.5.1 Company Details
  12.5.2 Performance Enhancing Drugs Product Offered
  12.5.3 Novo Nordisk Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.5.4 Main Business Overview
  12.5.5 Novo Nordisk News
12.6 BrainAlert
  12.6.1 Company Details
  12.6.2 Performance Enhancing Drugs Product Offered
  12.6.3 BrainAlert Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.6.4 Main Business Overview
  12.6.5 BrainAlert News
12.7 Douglas Laboratories
  12.7.1 Company Details
  12.7.2 Performance Enhancing Drugs Product Offered
  12.7.3 Douglas Laboratories Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.7.4 Main Business Overview
  12.7.5 Douglas Laboratories News
12.8 Onnit Labs
  12.8.1 Company Details
  12.8.2 Performance Enhancing Drugs Product Offered
  12.8.3 Onnit Labs Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.8.4 Main Business Overview
  12.8.5 Onnit Labs News
12.9 Eli Lilly And Company
  12.9.1 Company Details
  12.9.2 Performance Enhancing Drugs Product Offered
  12.9.3 Eli Lilly And Company Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
  12.9.4 Main Business Overview
  12.9.5 Eli Lilly And Company News

13 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Performance Enhancing Drugs
Table Product Specifications of Performance Enhancing Drugs
Figure Performance Enhancing Drugs Report Years Considered
Figure Market Research Methodo